AbbVie is part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership, as well as the COVID R&D Alliance. Abbvie medicines are being studied under both partnerships. They are also conducting antibody research, and are in collaboration with Harvard University in a research alliance to study and develop novel therapies against emergent viral infections. Find out more.
Boehringer Ingelheim immediately identified the areas of expertise, where they can best contribute to developing therapies for COVID-19 in close collaboration with academic researchers, international institutions and others in the pharma industry.
BI has joined a fast track call for project submissions to develop therapies and diagnostic tools initiated by the Innovative Medicines Initiative (IMI) of the European Union to accelerate the development of potential therapies for COVID-19.
They are also working to develop neutralizing antibodies and investigating existing pipeline and in-market compounds as well as compounds from former research activities.
Johnson & Johnson. In partnership with the Rega Institute for Medical Research, University of Leuven (Belgium), J&J is working to identify existing or new compounds with antiviral activity against COVID-19.
Pfizer is evaluating an antiviral compound – a 'protease inhibitor' identified by Pfizer scientists in 2003 – as a treatment for COVID-19. This potential treatment interrupts the virus’ ability to multiply. Find out more.
Pfizer also outlined a detailed 5-point action plan to battle COVID-19. The plan includes a commitment to sharing its clinical development and regulatory expertise to support other smaller biotech companies that are screening compounds or existing therapies for activity against the virus causing COVID-19.
Takeda and several other companies are working together in the CoVIg-19 Plasma Alliance and are currently conducting a phase 3 trial of an Anti-Coronavirus Immunoglobulin (ITAC).
The trial will evaluate the safety, tolerability and efficacy of an investigational anti-coronavirus hyperimmune intravenous immunoglobulin (H-Ig) medicine for treating hospitalized adults at risk for serious complications of COVID-19 disease. Find out more.
AstraZeneca is working with the National Institute of Health Research (NIHR) on a Phase 3 trial to investigate monoclonal antibodies for the treatment of COVID-19. The study is one of two national priority trials focused on the treatment of two investigational antibodies, known as AZD7442. Find out more.
Eli Lilly and AbCellera have co-developed an antibody product for the treatment and prevention of COVID-19, which has now received FDA emergency use authorization for the treatment of recently diagnosed COVID-19. Find out more.
GSK is a member of the collaborative research effort, the COVID-19 Therapeutics Accelerator. They are also collaborating with Vir Biotechnology to develop new dual action monoclonal antibodies and looking at own marketed pharmaceutical products and medicines in development to determine if any could be used in response to the pandemic. Find out more.
MSD is advancing the development and manufacturing of two investigational therapeutics - a novel immune modulator candidate, and in collaboration with Ridgeback Bio, a novel antiviral candidate. Find out more.
Novartis is a member of the collaborative research effort, the COVID-19 Therapeutics Accelerator, coordinated by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard, as well as a COVID-19 directed partnership organized by the Innovative Medicines Initiative. Find out more.
Novartis is also collaborating with Molecular Partners to develop two potential antiviral treatments for COVID-19 based on a new class of protein therapeutics. Find out more.
Roche is investigating its existing portfolio in relation to COVID-19. It has confirmed initiation of multiple clinical trials, and is also collecting and compiling data from other, independently led, clinical trials that are taking place around the world, as well as partnering with other companies and research organisations. Find out more.